Close Menu

NEW YORK (GenomeWeb) – Natera has filed with the US Securities and Exchange Commission for a proposed $100 million common stock offering.

The San Carlos, California-based molecular diagnostics firm filed the automatic shelf registration statement at the close of the market Tuesday. Based on its closing price of $20.28 on Monday, Natera said that it would offer around 4.9 million shares.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.